Tiziana Life SciencesTLSA +2.93%30 3-Year RORE % is -2.27 as of Dec. 2025. GuruFocus rates TLSA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,295 Biotechnology companies, Tiziana Life Sciences ranks better than 61.62% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Tiziana Life Sciences's 3-Year RORE % for the quarter that ended in Dec. 2025 was -2.27%.
The industry rank for Tiziana Life Sciences's 3-Year RORE % or its related term are showing as below:
TLSA's 3-Year RORE % is ranked better than 61.62% of 1295
companies
in the Biotechnology industry
Industry Median: -11.53
vs TLSA: -2.27
Tiziana Life Sciences (NAS:TLSA) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Tiziana Life Sciences 3-Year RORE % Related Terms
Tiziana Life Sciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Tiziana Life Sciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLSA vs SPRB, MIST, TNYA: 3-Year RORE % Comparison
For the Biotechnology subindustry, Tiziana Life Sciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tiziana Life Sciences 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Tiziana Life Sciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Tiziana Life Sciences (TLSA) has a 3-Year RORE % of -2.27 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Tiziana Life Sciences and its competitors. According to the industry distribution chart, Tiziana Life Sciences ranks #497 out of 1295 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Tiziana Life Sciences' 3-Year RORE % too high?
Tiziana Life Sciences' current 3-Year RORE % is -2.27. Based on the distribution chart, Tiziana Life Sciences ranks #497 out of 1295 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tiziana Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Tiziana Life Sciences' 3-Year RORE % compare to SPRB and MIST?
According to the Biotechnology industry distribution chart, Tiziana Life Sciences ranks #497 out of 1295 companies for 3-Year RORE %. This puts Tiziana Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Tiziana Life Sciences and its competitors. Tiziana Life Sciences's current 3-Year RORE % is -2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tiziana Life Sciences stock overvalued right now?
Tiziana Life Sciences (TLSA) has a current 3-Year RORE % of -2.27. The current 3-Year RORE % is -2.27. Tiziana Life Sciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Tiziana Life Sciences (TLSA), the current 3-Year RORE % is -2.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
30GF Score
Get the complete analysis for TLSA
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSA has been successfully added to your 
